Asymptomatic Unruptured Intracranial Aneurysms

Peter Whitfield, Ph.D.

There is widespread consensus that asymptomatic unruptured aneurysms carry a substantial risk of rupture and require treatment. In contrast, the management of a patient with an asymptomatic unruptured aneurysm (AUA) remains controversial. If all AUAs could be successfully obliterated with minimal morbidity and mortality the catastrophic consequences of a subarachnoid haemorrhage could be safely averted. However, the attendant risks of treatment may outweigh the potential benefits of aneurysm exclusion. Therefore it is important to appraise the natural history of these lesions if left untreated and balance this against the risks of treatment when formulating an evidence-based management plan.

Epidemiology

Epidemiological data can help estimate the risk of AUA rupture. Past mortality and angiographic studies report that AUAs are found in approximately 1-6% of the population.1 The variability in incidence may be attributed to geographic and age profile differences in the populations studied in addition to case selection, technical and observer factors. In a systematic review Tunell et al. conclude that the prevalence of AUAs in adults without specific risk factors is 2.9%.2

A population-based study with stringent case ascertainment indicates that the incidence of aneurysmal subarachnoid haemorrhage is 7.4/100 000 men and 13.9/100 000 women in South West England, with an overall rate of 9.7/100 000.3 The relatively high prevalence of AUAs and low incidence of subarachnoid haemorrhage indicates that most AUAs do not rupture.

If aneurysmal subarachnoid haemorrhages (1/10000 per annum) are considered to originate from AUAs and the prevalence of AUAs is considered to be 2.3%, the risk of rupture can be estimated at 0.4% per annum. This may be an overestimate due to the unknown number of cases of rapid de novo aneurysm formation, expansion and rupture with no significant time spent in an AUA phase. In addition, risk factors (smoking, hypertension, polycystic kidney disease) will increase the rupture rate in some patients. Assuming that virtually all AUAs and SAH cases occur in the 60% of the population over the age of 30 years, the incidence of SAH in adults can be approximated to 1 in 4000 while the prevalence of AUAs is 1 in 26 in this population. This again infers that less than 0.5% of AUAs will rupture per annum.

Natural History Studies

It is difficult to study the natural history of AUAs both due to the longevity required, cases lost to follow-up and the fact that cohort studies may carry significant bias due to the exclusion of patients selectively treated and not recruited for follow-up. In such studies 2 groups of patients are characterized: those with an incidental AUA and cases with an additional AUA. The latter group have previously had aneurysmal SAH from a separately treated culprit aneurysm. Valuable follow-up data in 142 patients with 181 unruptured intracranial aneurysms with prolonged follow-up has been reported from Scandinavia (mean follow-up 19.7 years, range 0.8 – 30.9 years, 109 cases studied for at least 10 years).4 The majority (n = 121) of these cases were additional aneurysm patients. Of these, 30 patients experienced a further SAH during follow-up. This was calculated to represent an annual rupture incidence of 1.3%. The risk factors for haemorrhage were age (inverse relationship), increasing aneurysm size and smoking. This study did not provide any robust information about the rupture risk from incidental AUAs.

The International Study of Unruptured Intracranial Aneurysms (ISUA) is a 53-centre study that has provided natural history data.5 The 1449 retrospectively studied patients presenting between 1970 and 1991 showed that the incidence of rupture in patients with incidental anterior circulation aneurysms <10 mm in diameter was 0.05% per annum. In patients with similar size aneurysms and a previous SAH the rupture risk was 0.5% per annum. The rupture rates for aneurysms between 10-15mm approached 1% for both groups.6 While it may seem that over 3 decades the risk would be around 30%, mathematical probability indicates that it is lower at around 22%. These retrospective findings indicate a much lower rupture rate than previously reported. Although inclusion bias has been cited as a possible reason for these results, many clinicians have adopted a more conservative approach in response to this evidence.

The prospective component of the ISUA study with recruitment between 1991-1998 followed up 1692 patients who had conservative management of incidental (1057 cases) or additional (635 cases) AUAs for an average of 4.1 years.7 Interestingly the incidental aneurysms were generally larger than the additional lesions. Of the 51 patients (3%) that sustained a SAH during follow-up, 41 had incidental aneurysms with no history of previous SAH (80.5%). Only 10 (1.6%) cases in the additional aneurysm group sustained a SAH. The large number of very small aneurysms in this group (80% compared to 50% in the incidental aneurysm group) probably explains the lower bleed rate. While a previous SAH has been shown to be associated with a higher risk of AUA rupture in the retrospective cohort the small numbers of prospectively observed bleeds in this group does not add credence to this conclusion. This study also reported several other notable findings related to aneurysm size and location.

1. Incidental aneurysms less than 7 mm in diameter very rarely rupture (n = 2). Both ruptured aneurysms in this size range were posterior communicating artery aneurysms. Since no other 2 – 7 mm incidental anterior circulation aneurysms ruptured, posterior communicating artery aneurysms were speculated to carry a higher risk of bleeding and were subsequently analysed with posterior circulation aneurysms. Seven of the 10 ruptured additional aneurysms were in the 2-7 mm size bracket.

2. Larger incidental aneurysms are more likely to bleed. This conclusion was largely based upon the findings in patients with incidental aneurysms. The numbers of ruptures in the additional aneurysm group were too small to comment upon the importance of size.

3. Aneurysms in the posterior circulation had a higher rate of rupture. The 5-year rupture rates are summarised in Table 1. In essence the annual risk of a bleed was less than 1% for aneurysms up to 12 mm diameter, only increasing to

Table: 5-year cumulative rupture rates according to size and location of unruptured aneurysms (data from ISUA study).

<table>
<thead>
<tr>
<th>Aneurysm Location</th>
<th>&lt;7mm</th>
<th>7-12mm</th>
<th>&gt;12mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior circulation (inc. P comm.)</td>
<td>0</td>
<td>1.5%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Posterior circulation (inc. P comm.)</td>
<td>2.9%</td>
<td>3.4%</td>
<td>14.5%</td>
</tr>
</tbody>
</table>

Correspondence to:
Peter Whitfield
Ph: +44 01707 359 868
Email: pwhitfield66@btinternet.com

Clinical interest include vascular neurosurgery, image guided neurosurgery and micro-surgical arterial surgery.
around 3% for lesions 13-24 mm. The rupture rate for giant aneurysms was around 10% per annum.

It is important to recognise that the ISUIA study was not a randomised-controlled trial and that many patients eligible for conservative observation were selected for surgical intervention or endovascular therapy. In addition, the use of inclusion criteria and the unknown recruitment rate question the applicability of the findings to the wider population. Despite these caveats the study does provide the best natural history data available. Future reports from ISUIA with longer follow-up will enhance the quality of the data.

**Operative and endovascular treatment risks**

The reporting of procedural risks is imperfect due to publication bias and criticisms of study design. Whilst the International Cooperative Study on aneurysmal SAH compared surgical treatment with overall management outcome in a cohort of 3500 cases such information is not directly applicable to the AUIA population.  Similarly the ISAT trial was targeted at patients treated after a subarachnoid haemorrhage. The most robust information again arises from the prospective cohort of the ISUIA study where outcome was recorded in 1917 cases undergoing aneurysm clipping and 451 cases treated with endovascular coiling recruited between 1994 and 1998. Risk factors for a poor outcome were posterior fossa aneurysm location, size greater than 12mm and (for surgical patients only) age. A considerable proportion of endovascular treatments only achieved partial occlusion: the long-term durability of this treatment remains under scrutiny. Overall, poor outcomes were reported in around 5-6% of clipped small and medium sized anterior circulation aneurysms in patients less than 50 years of age. Age over 50 years doubled the frequency of poor outcomes following clipping of small aneurysms. The poor outcome rate increased to around 25% for patients over 50 years with medium sized aneurysms. Mortality from posterior fossa aneurysm surgery was even greater. Endovascular clipping of small and medium sized anterior circulation aneurysms carried a 7-8% risk of a poor outcome in patients less than 50 years old. Although these results suggest that small aneurysms are best treated with clipping it should be remembered that the patients were selected and not randomised to different treatment modalities. Giant aneurysms were rare but the risks of a poor outcome with endovascular treatment were around 15% with wide confidence limits.

**Risk assessment**

ISUIA and ISAT's cohort study have provided an estimate of aneurysm rupture rates over a period of time. ISUIA has also provided data on treatment outcomes in patients undergoing prophylactic aneurysm treatment. For each individual the risk of treatment needs to be balanced against the risk of rupture. Using the ISUIA data and predicted life expectancy derived from the 2001 UK census, Mitchell's group plotted outcome predictive curves where

---

**Table 2: Screening for incidental intracranial aneurysms**

<table>
<thead>
<tr>
<th>SCREENING ISSUES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease should be common</td>
<td>SAH is rare incidence 1:10 000 per annum</td>
</tr>
<tr>
<td>Disease should carry substantial morbidity</td>
<td>Mortality and mortality of SAH is substantial</td>
</tr>
<tr>
<td>Screening test should be acceptable</td>
<td>CT angiography is acceptable, sensitive and specific. Invasive angiography is not an acceptable low risk test</td>
</tr>
<tr>
<td>An effective preventative treatment is available</td>
<td>Coiling and clipping carry substantial risks</td>
</tr>
<tr>
<td>Lead-time bias</td>
<td>This is the time between diagnosis and onset of symptoms. If an aneurysm is identified but not treated the lead-time bias is increased by an infinite amount. Psychological morbidity may be considerable</td>
</tr>
<tr>
<td>Length bias</td>
<td>Screening may detect a large number of patients with stable low risk aneurysms and miss aneurysms that develop or expand quickly</td>
</tr>
</tbody>
</table>
“Life years saved or lost by aneurysm repair” was plotted against age at time of treatment (see Figures 1 and 2).6 Inspection of the curves enables the clinician to ascertain the relative risks of treatment versus the saving of life years. For example, life years are saved by endovascular treatment of incidental anterior circulation aneurysms in the 13-24 mm range for patients under the age of 65 years. This model is based on the assumption that aneurysm occlusion provides robust protection from rebleeds. It does not address the cost-benefit ratio of treatment.

Aneurysm screening

Genetic factors appear to be important in the causation of intracranial aneurysms. Therefore, screening relatives of SAH victims might seem an approach worthy of consideration. However, many factors need to be considered (Table 2).

In a useful review paper, White and Wardlaw conclude that only 156/21054 (0.74%) of first-degree relatives sustain a SAH in population-based longitudinal studies.4 A recent Scottish study reported the 10-year prospective risk of sustaining a SAH for a first-degree relative of an index case as 1.2% (95% CI: 0.4 – 2%). The risk for second-degree relatives was 0.5% (CI: 0.1 – 0.8%).40 There was a trend for the risk to be highest in families with two first-degree relatives affected and lowest if only one second-degree relative was affected. On this basis screening for aneurysms should only be offered to patients over 30 years old in families with 2 or more first-degree relatives with a history of SAH. If only 1 first-degree relative has sustained a SAH, screening is not recommended. Other at-risk patients (e.g., adult polycystic kidney disease) should be advised on an individual basis. Due to the high sensitivity and specificity, rapid acquisition time and low procedural risks (x-ray exposure) CT angiography is now our screening investigation of choice, replacing invasive digital subtraction angiography and MR angiography.

Summary and case study

High quality studies have helped to improve our knowledge of the natural history and treatment risks in patients with AUsAs. Knowledge of this literature is essential to formulate an evidence-based management plan applicable to the individual patient. Factors such as life expectancy, aneurysm location and size, combined with the individual’s attitude to risk will govern the approach selected (Figure 3).

Interdisciplinary teamwork between neurosurgeons and neuroradiologists is crucial to optimise evidence-based management. Widespread screening is not recommended and should be reserved for high-risk cases after discussion with the patient.

References


Interdisciplinary teamwork between neurosurgeons and neuroradiologists is crucial to optimise evidence-based management.